GC
Gregory Charles Vella
About Gregory Charles Vella
Data last updated:
Gregory Charles Vella is a Director at Avance Clinical India Private Limited (since 2022). The company operates in Healthcare. Avance Clinical India Private Limited reported revenue of ₹9.35 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Avance Clinical India Private Limited U73100KA2022FTC167429 | Director | 28 Oct 2022 | 2022 | ₹9.35 Cr (FY 2025) | Active |
Board colleagues of Gregory Charles Vella
| Name | DIN | Company | Designation |
|---|---|---|---|
| Mark Landon Harvill | 11219851 | Avance Clinical India Private Limited | Additional Director |
| Yadehalli Gundurao Ramya | 10330968 | Avance Clinical India Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Gregory Charles Vella
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gregory Charles Vella
Gregory Charles Vella currently holds 1 directorship: Avance Clinical India Private Limited (Director, since 28 Oct 2022, revenue ₹9.35 Cr (FY 2025)).
Gregory Charles Vella was first appointed on 28 Oct 2022 as Director at Avance Clinical India Private Limited.
The current boards of Gregory Charles Vella's companies include Mark Landon Harvill (Avance Clinical India Private Limited), Yadehalli Gundurao Ramya (Avance Clinical India Private Limited).